Associated tags: Transfer, Skin cancer, Diagnosis, AI, Mayo, Telehealth, US Food Sovereignty Alliance, Mayo Clinic, Pharmacy, Food, OTD, FDA, Teledermatology, Skin, Biopsy, Medical device, Medical imaging, Dermatology
Mayo,
Telehealth,
US Food Sovereignty Alliance,
Mayo Clinic,
Diagnosis,
Pharmacy,
Food,
Skin cancer,
OTD,
FDA,
Teledermatology,
Skin,
Biopsy,
Medical device,
Medical imaging,
Dermatology WASHINGTON, June 6, 2023 /PRNewswire/ -- DeepX Diagnostics Inc., the skin cancer teledermatology and diagnostics company, announced today that its digital dermatoscope DermoSightTM received clearance from the US Food and Drug Administration (FDA) for teledermatology screening of suspect skin cancer lesions in the United States. The company is now ready to enter the US market on the back of over 180 thousand assessments in pharmacies and primary care clinics in Europe.
Key Points:
- DeepX Diagnostics Inc. to enter US market, having already performed over 180,000 skin lesions assessments in pharmacy and primary care to date in Europe.
- WASHINGTON, June 6, 2023 /PRNewswire/ -- DeepX Diagnostics Inc., the skin cancer teledermatology and diagnostics company, announced today that its digital dermatoscope DermoSightTM received clearance from the US Food and Drug Administration (FDA) for teledermatology screening of suspect skin cancer lesions in the United States.
- DermoSight is currently cleared to acquire skin lesion images for teledermatology assessment, like existing digital dermatoscopes.
- It will help people with skin lesions of concern receive early diagnosis and effective treatment of skin cancer," said Christian Horn, the CEO at DeepX Diagnostics.
Mayo,
Telehealth,
US Food Sovereignty Alliance,
Mayo Clinic,
Diagnosis,
Pharmacy,
Food,
Skin cancer,
OTD,
FDA,
Teledermatology,
Skin,
Biopsy,
Medical device,
Medical imaging,
Dermatology WASHINGTON, June 6, 2023 /PRNewswire/ -- DeepX Diagnostics Inc., the skin cancer teledermatology and diagnostics company, announced today that its digital dermatoscope DermoSightTM received clearance from the US Food and Drug Administration (FDA) for teledermatology screening of suspect skin cancer lesions in the United States. The company is now ready to enter the US market on the back of over 180 thousand assessments in pharmacies and primary care clinics in Europe.
Key Points:
- DeepX Diagnostics Inc. to enter US market, having already performed over 180,000 skin lesions assessments in pharmacy and primary care to date in Europe.
- WASHINGTON, June 6, 2023 /PRNewswire/ -- DeepX Diagnostics Inc., the skin cancer teledermatology and diagnostics company, announced today that its digital dermatoscope DermoSightTM received clearance from the US Food and Drug Administration (FDA) for teledermatology screening of suspect skin cancer lesions in the United States.
- DermoSight is currently cleared to acquire skin lesion images for teledermatology assessment, like existing digital dermatoscopes.
- It will help people with skin lesions of concern receive early diagnosis and effective treatment of skin cancer," said Christian Horn, the CEO at DeepX Diagnostics.
